InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$15.61+3.41 (+27.94%)
Close on Nov 11, 2026Market cap $85.75MP/E –Yield –
InMed Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
InMed Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2023 was -147.9%. For fiscal 2023 it was -192.2%, against -1707.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | -192.2% | +1515.1 |
| FY2022 | Jun 30, 2022 | -1707.3% | −1171.4 |
| FY2021 | Jun 30, 2021 | -535.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -281.3% | +813.0 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -14.6% | +1514.2 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -193.2% | +929.4 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -447.2% | +1168.3 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -1094.2% | −724.2 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -1528.9% | −819.7 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -1122.7% | −312.0 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -1615.6% | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -370.0% | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -709.2% | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -810.6% | – |
See a number that looks wrong?